Fairmont Hotel Vancouver Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
Here are the related meetings in 2020:
Emerging Cellular Therapies: Cancer and Beyond (Q1)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Cancer Vaccines (L2)
Organizer(s) Lélia Delamarre, Robert A. Seder and Nina Bhardwaj
January 20—24, 2019
Fairmont Hotel Vancouver • Vancouver, BC Canada
Discounted Abstract Deadline: Oct 16, 2018
Abstract Deadline: Oct 24, 2018
Scholarship Deadline: Oct 16, 2018
Discounted Registration Deadline: Nov 27, 2018
Organized in collaboration with Cancer Research UK
Sponsored by BioLegend, Inc., Genentech, Inc. and Pfizer Inc.
Sponsored by BioLegend, Inc., Genentech, Inc. and Pfizer Inc.
Summary of Meeting:
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.
View Scholarships/Awards
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, January 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 25 in order to fully experience the meeting.
SUNDAY, JANUARY 20
MONDAY, JANUARY 21
TUESDAY, JANUARY 22
WEDNESDAY, JANUARY 23
THURSDAY, JANUARY 24
FRIDAY, JANUARY 25
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, January 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 25 in order to fully experience the meeting.
SUNDAY, JANUARY 20
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:30—10:00
Welcome and Keynote Session
*
Lélia Delamarre,
Genentech, Inc., USA
*
Robert A. Seder,
NIAID, National Institutes of Health, USA
*
Nina Bhardwaj,
Icahn School of Medicine at Mount Sinai, USA
Glenn Dranoff,
Novartis Institutes for BioMedical Research, USA
Cancer Vaccines: Overview
Cancer Vaccines: Overview
Ira Mellman,
Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy
The Mechanistic Basis of Cancer Immunotherapy
Coffee Break
10:20—12:30
Identification of Mutated Neoantigens
*
Glenn Dranoff,
Novartis Institutes for BioMedical Research, USA
Timothy A. Chan,
Memorial Sloan Kettering Cancer Center, USA
Mutations and Neoantigens in Cancer Immunotherapy
Mutations and Neoantigens in Cancer Immunotherapy
Karin U. Jooss,
Gritstone Oncology, USA
Driving CD8+ T Cell Responses to Mutational Neoantigens in Tumors - Harnessing Immunogenic Viral Vectors
Driving CD8+ T Cell Responses to Mutational Neoantigens in Tumors - Harnessing Immunogenic Viral Vectors
Lélia Delamarre,
Genentech, Inc., USA
Determinants of Cancer Neoantigen Immunogenicity
Determinants of Cancer Neoantigen Immunogenicity
Binbin Chen,
Stanford Medical School, USA
Short Talk: MARIA: Deep Neural Network Predicting HLA Class II Antigen Presentation for Personalized Cancer Vaccines
Short Talk: MARIA: Deep Neural Network Predicting HLA Class II Antigen Presentation for Personalized Cancer Vaccines
Lisa McNeil,
Genocea Biosciences, USA
Short Talk: ATLAS™ Identifies Stimulatory and Inhibitory Neoantigens with Opposing Effects in a Murine Challenge Model
Short Talk: ATLAS™ Identifies Stimulatory and Inhibitory Neoantigens with Opposing Effects in a Murine Challenge Model
14:30—16:30
Workshop 1: Cancer Antigens and Immune Monitoring
Samuel J. Landry,
Tulane University Health Sciences Center, USA
CD4+ Epitope Prediction Limited by Analysis of Antigen Conformational Flexibility
CD4+ Epitope Prediction Limited by Analysis of Antigen Conformational Flexibility
*
Aude-Helene Capietto,
Genentech, Inc., USA
Characterization of the Immunogenic Determinants of Tumor Neoantigens Improves their Identification
Characterization of the Immunogenic Determinants of Tumor Neoantigens Improves their Identification
Cansu Cimen Bozkus,
Icahn School of Medicine at Mount Sinai, USA
Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms
Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms
Russell Kent Pachynski,
Washington University in St. Louis, USA
A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer
A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer
Brandon Coder,
Advaxis, USA
Neoantigen Prioritization for Use in a Listeria Monocytogenes Cancer Vaccine
Neoantigen Prioritization for Use in a Listeria Monocytogenes Cancer Vaccine
Ghislain Bonamy,
immunoSCAPE, Singapore
Leveraging the Multi-Parametric Profiling Capacity of Mass Cytometry to Query the Specificity of Tumor-Infiltrating T-Cells
Leveraging the Multi-Parametric Profiling Capacity of Mass Cytometry to Query the Specificity of Tumor-Infiltrating T-Cells
17:00—19:00
Other Cancer Antigens
*
Lélia Delamarre,
Genentech, Inc., USA
Stephen B. Baylin,
Johns Hopkins University School of Medicine, USA
Immunogenicity of Transposable Elements in Cancer – Relevance to Epigenetic Therapy
Immunogenicity of Transposable Elements in Cancer – Relevance to Epigenetic Therapy
Victor H. Engelhard,
University of Virginia, USA
Post-Translationally Modified Cancer Neoantigens
Post-Translationally Modified Cancer Neoantigens
Cornelia Liu Trimble,
Johns Hopkins University School of Medicine, USA
Targeting HPV Antigens by Vaccination
Targeting HPV Antigens by Vaccination
Haiyin Chen,
Genentech, Inc., USA
Short Talk: Transposable Element Expression in Tumors Is Associated with Immune Infiltrate and Increased Antigenicity
Short Talk: Transposable Element Expression in Tumors Is Associated with Immune Infiltrate and Increased Antigenicity
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Priming T Cells
*
Sebastian Amigorena,
Institut Curie, France
Rafi Ahmed,
Emory University School of Medicine, USA
T Cell Exhaustion and PD-1 Immunotherapy
T Cell Exhaustion and PD-1 Immunotherapy
E. John Wherry,
University of Pennsylvania, USA
The Developmental Program of Exhausted T Cells
The Developmental Program of Exhausted T Cells
Coffee Break
Pedro Romero,
University of Lausanne, Switzerland
Programming T Cell Memory for Immunotherapy of Cancer
Programming T Cell Memory for Immunotherapy of Cancer
David B. Masopust,
University of Minnesota, USA
Repurposing Antiviral T Cells to Fight Tumors
Repurposing Antiviral T Cells to Fight Tumors
John P. Finnigan,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Molecular and Cellular Properties of Neoantigen-Specific CD8+ T Cells Interacting with Melanoma in situ
Short Talk: Molecular and Cellular Properties of Neoantigen-Specific CD8+ T Cells Interacting with Melanoma in situ
Jared Klarquist,
University of Colorado Denver, USA
Short Talk: Vaccine-Elicited T Cells Expand and Function Independently of Aerobic Glycolysis: Implications for Therapeutic Cancer Vaccines
Short Talk: Vaccine-Elicited T Cells Expand and Function Independently of Aerobic Glycolysis: Implications for Therapeutic Cancer Vaccines
14:30—16:30
Workshop 2: Vaccine Platforms
*
Karin Loré,
Karolinska Institutet, Sweden
Jaehak Oh,
Genentech, Inc., USA
RNA-Lipoplex Vaccine Is Presented on MHCI and MHCII Molecules of Differential Dendritic Cell Subsets in Spleen
RNA-Lipoplex Vaccine Is Presented on MHCI and MHCII Molecules of Differential Dendritic Cell Subsets in Spleen
Yanling Xiao,
Netherlands Cancer Institute, Netherlands
Antigen Cross-Presentation and T-Cell Priming Ability of Human Dendritic Cells Generated in vitro from a Newly Discovered Oligopotent Progenitor of Granulocytes, Macrophages, Osteoclasts and Dendritic Cells
Antigen Cross-Presentation and T-Cell Priming Ability of Human Dendritic Cells Generated in vitro from a Newly Discovered Oligopotent Progenitor of Granulocytes, Macrophages, Osteoclasts and Dendritic Cells
Faezzah Baharom,
National Institutes of Health, USA
Route, Dose and Agonist Potency Influence the Induction of TCF1+ Neoantigen-Specific CD8 T Cells by Peptide-TLR7/8 Agonist Nanoparticle Vaccine
Route, Dose and Agonist Potency Influence the Induction of TCF1+ Neoantigen-Specific CD8 T Cells by Peptide-TLR7/8 Agonist Nanoparticle Vaccine
Anna Morena D'Alise,
Nouscom Srl, Italy
Novel Adenovector Vaccine Targeting Multiple Neoantigens Eeradicates Large Tumors in Mice in Combination with Checkpoint Blockade
Novel Adenovector Vaccine Targeting Multiple Neoantigens Eeradicates Large Tumors in Mice in Combination with Checkpoint Blockade
Robert Petit,
Advaxis Inc., USA
Magnitude of Anti-PSA T Cell Response Is Associated with Antigen Spreading and Slowing in PSA and PAP Velocity
Magnitude of Anti-PSA T Cell Response Is Associated with Antigen Spreading and Slowing in PSA and PAP Velocity
Alessia Melacarne,
Humanitas University, Italy
Antigens Released by Salmonella-Infected Tumor Cells as a Novel Vaccine Platform
Antigens Released by Salmonella-Infected Tumor Cells as a Novel Vaccine Platform
Aymen Al-shamkhani,
University of Southampton, UK
The Effects of Akt/Protein Kinase B on Effector and Memory CD8 T Cell Differentiation Revealed by Single Cell RNA-Seq
The Effects of Akt/Protein Kinase B on Effector and Memory CD8 T Cell Differentiation Revealed by Single Cell RNA-Seq
17:00—19:00
Antigen-Presenting Cells
*
Ira Mellman,
Genentech, Inc., USA
Karin Loré,
Karolinska Institutet, Sweden
Understanding Innate Immune Mechanisms Dictating Vaccine Responses
Understanding Innate Immune Mechanisms Dictating Vaccine Responses
Sebastian Amigorena,
Institut Curie, France
Dendritic Cell Biology
Dendritic Cell Biology
Marc Y. Dalod,
Centre National de la Recherche Scientifique, France
Deciphering the Role of cDC1 in Anti-Tumor Immunity
Deciphering the Role of cDC1 in Anti-Tumor Immunity
Zwi N. Berneman,
Antwerp University Hospital, Belgium
Short Talk: Vaccination of Cancer Patients with WT1 mRNA-Electroporated Dendritic Cells: Correlation of Clinical Effect and Overall Survival with T-Cell Response
Short Talk: Vaccination of Cancer Patients with WT1 mRNA-Electroporated Dendritic Cells: Correlation of Clinical Effect and Overall Survival with T-Cell Response
Matthew G. Booty,
SQZ Biotechnologies, USA
Short Talk: SQZ'ing Cells to Engineer a New Generation of Cancer Vaccines
Short Talk: SQZ'ing Cells to Engineer a New Generation of Cancer Vaccines
08:30—11:30
Novel Cancer Vaccine Platforms I
*
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
David B. Weiner,
Wistar Institute, USA
DNA-Based Vaccines
DNA-Based Vaccines
John C. Bell,
Ottawa Hospital Research Institute, Canada
Virus-Based Vaccines
Virus-Based Vaccines
Coffee Break
Ugur Sahin,
BioNTech AG, Germany
RNA-Based Vaccines
RNA-Based Vaccines
Robert A. Seder,
NIAID, National Institutes of Health, USA
Peptide-TLR 7/8 Agonist Vaccines Chemically Programmed to Enhance the Magnitude, Quality and Breadth of Neoantigen CD8 T Cell Responses
Peptide-TLR 7/8 Agonist Vaccines Chemically Programmed to Enhance the Magnitude, Quality and Breadth of Neoantigen CD8 T Cell Responses
Christian J. Maine,
Janssen R&D, USA
Short Talk: Self-Amplifying RNA Polytope Vaccines Can Elicit Anti-Tumor T Cell Responses Against Neoantigens for Cancer Immunotherapy
Short Talk: Self-Amplifying RNA Polytope Vaccines Can Elicit Anti-Tumor T Cell Responses Against Neoantigens for Cancer Immunotherapy
17:00—19:00
Novel Cancer Vaccine Platforms II
*
Robert A. Seder,
NIAID, National Institutes of Health, USA
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Building Better Personal Cancer Vaccines
Building Better Personal Cancer Vaccines
Nina Bhardwaj,
Icahn School of Medicine at Mount Sinai, USA
DC Targeted Vaccines
DC Targeted Vaccines
Joshua Tobias,
Medical University of Vienna, Austria
Short Talk: A Paradigm Change in Cancer Immunotherapy: Combined B Cell Epitope Peptides of Her-2/neu and Immune Checkpoint Inhibitors for Active Immunization
Short Talk: A Paradigm Change in Cancer Immunotherapy: Combined B Cell Epitope Peptides of Her-2/neu and Immune Checkpoint Inhibitors for Active Immunization
Mubeen M. Mosaheb,
Duke University, USA
Short Talk: A Poliovirus-Based Recombinant Vector Activates Antigen-Presenting Cells and Primes Anti-Tumor T Cell Immunity
Short Talk: A Poliovirus-Based Recombinant Vector Activates Antigen-Presenting Cells and Primes Anti-Tumor T Cell Immunity
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Tumor Microenvironment and Combination Therapies
*
Nina Bhardwaj,
Icahn School of Medicine at Mount Sinai, USA
Shannon J. Turley,
Genentech, Inc., USA
TGFbeta in Cancer
TGFbeta in Cancer
Coffee Break
Thomas Gajewski,
University of Chicago, USA
Downstream Regulation at the Level of the Tumor Microenvironment
Downstream Regulation at the Level of the Tumor Microenvironment
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Combination Therapies Inducing a Self-Sustaining Vaccinal Cycle
Combination Therapies Inducing a Self-Sustaining Vaccinal Cycle
Linda Hammerich,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: In situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors via Induction of Antigen Cross-Presentation by Dendritic Cells
Short Talk: In situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors via Induction of Antigen Cross-Presentation by Dendritic Cells
Bin Liu,
University of California, Los Angeles, USA
Short Talk: Combination of in situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) and Anti-PD1 for Non-Small Cell Lung Cancer (NSCLC)
Short Talk: Combination of in situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) and Anti-PD1 for Non-Small Cell Lung Cancer (NSCLC)
14:30—16:30
Workshop 3: Combination Therapies
*
Joshua D. Brody,
Icahn School of Medicine at Mount Sinai, USA
Selma Bekri,
Icahn School of Medicine at Mount Sinai, USA
Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of a Neoantigen Vaccine for Multiple Myeloma
Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of a Neoantigen Vaccine for Multiple Myeloma
Elham Beyranvand Nejad,
Leiden University Medical Center, Netherlands
Non-Curative Immunotherapy Drives the Development of Immune-Deserted Recurrences
Non-Curative Immunotherapy Drives the Development of Immune-Deserted Recurrences
Rosmely Hernandez,
University of Miami Miller School of Medicine, USA
IL-2-Dependent Amplification of T Effector and Memory Responses to Promote Anti-Tumor Immunity
IL-2-Dependent Amplification of T Effector and Memory Responses to Promote Anti-Tumor Immunity
Zhen Zeng,
University of Queensland, Australia
The Involvement of IFN-γ and CXCR3 in the CD8+ T-Cell-Mediated Regression of Squamous Cell Carcinoma
The Involvement of IFN-γ and CXCR3 in the CD8+ T-Cell-Mediated Regression of Squamous Cell Carcinoma
Ramin Salehi-Rad,
University of California, Los Angeles, USA
Tumor Vaccination with CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Checkpoint Blockade in Murine Models of NSCLC with Varying Mutational Load
Tumor Vaccination with CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Checkpoint Blockade in Murine Models of NSCLC with Varying Mutational Load
17:00—18:45
Immune Monitoring of T Cells
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers
Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers
Sjoerd H. van der Burg,
Leiden University Medical Center, Netherlands
NKG2A Blockade Potentiates CD8+ T-Cell Immunity Induced by Therapeutic Cancer Vaccines
NKG2A Blockade Potentiates CD8+ T-Cell Immunity Induced by Therapeutic Cancer Vaccines
*
Evan W. Newell,
Fred Hutchinson Cancer Research Center, USA
Asking T Cells About What They See in Cancer
Asking T Cells About What They See in Cancer
Mark Klinger,
Adaptive Biotechnologies, USA
Short Talk: Optimization of Cancer Vaccine Development by using Multiplexed Identification of T-Cell Receptor Antigen Specificity (MIRA)
Short Talk: Optimization of Cancer Vaccine Development by using Multiplexed Identification of T-Cell Receptor Antigen Specificity (MIRA)
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
